Skip to main content

Table 1 Characteristics of the study patients

From: Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region

Characteristics (total patients = 91)  
Female, n (%) 80 (87.9)
Age, median (IQR) 49 (39–54)
Years of migraine history, median (IQR) 28.5 (20–34)
Years of CM history, median (IQR) 10 (4–19)
Baseline MHDs, median (IQR) 26.5 (20–30)
Baseline acute medication days, median (IQR) 21 (16–30)
Baseline NRS, median (IQR) 8 (7–9)
Aura, n (%) 28 (30.8)
Allodynia, n (%) 35 (38.5)
Medication overuse, n (%) 71 (78.0)
Previous preventive treatment failures, n (%)
 2 31 (43.1)
 3 24 (26.4)
 4 28 (30.8)
  > 4 8 (8.8)
Botulinum toxin failure, n (%) 39 (42.9)
Concurrent oral preventive treatments at baseline, n (%) 30 (33.0)
Obesity, n (%) 13 (14.3)
Sleep disturbances, n (%) 33 (36.3)
Depressive symptoms, n (%) 19 (20.9)
  1. CM indicates chronic migraine, IQR interquartile range, MHD monthly headache days, NRS Numerical Rating Scale